PLSEPulse Biosciences, Inc.
$53.80+206% 1Y
$53.80
$12.6652 weeks$55.20
The financials
Pulse Biosciences, Inc. by the numbers
Pulse Biosciences, Inc. (PLSE) reported revenue of $434K in Q2 2026 (quarter ended Jun 30, 2026). That came with a gross margin of 37% and net loss of $25M. For the full year FY2025, revenue was $350K and net income −$73M. Its largest product in Q2 2022 (quarter ended Jun 30, 2022) was System Products at $209K, 79% of the disclosed total, well ahead of Cycle Units Products at 21%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $434K | $0 | n/a |
| Gross profit | $161K | $0 | n/a |
| Operating income | −$25M | −$20M | n/a |
| Net income | −$25M | −$19M | n/a |
| Product | Revenue | Share |
|---|---|---|
| System Products | $209K | 79% |
| Cycle Units Products | $56K | 21% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q3 2023Total $0.00
Segment Latestyear on year
- Cycle Units Products$0.00$0.00year on year n/an/a
- System Products$0.00$0.00year on year n/an/a
Medical Instruments & Supplies
Ranks #21 of 21 by RyuScore